GlaxoSmithKline is investing 17.5 million euros in a venture fund focused on developing drugs for rare diseases in Europe, according to Reuters. The fund, Kurma Biofund II, is being led by French firm Kurma Life Sciences Partners, with other investors including CDC Enterprises, Idinvest Partners and New Enterprise Associates. The fund has raise 44 million euros to date, and will work with a network of European research institutes to boost innovative projects in the rare disease field.
What do you think? Join our discussion on LinkedIn, or leave a comment below. Want more from Total Orphan Drugs? Sign up to our newsletter – it doesn’t cost anything and only takes a minute. If you want to know more about innovation and strategy in the orphan drug market, you might be interested in attending the 4th World Orphan Drug Congress Europe, Geneva, 14th November 2013.